MicroRNA-210 and its theranostic potential

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 11, 2016, Pages 1325-1338

  Ren, Chun Xia ^a   Leng, Rui Xue ^a   Fan, Yin Guang ^a   Pan, Hai Feng ^a   Wu, Chang Hao ^b   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

biomarker; hypoxia; MicroRNA 210; theranostic target

Indexed keywords

CCN PROTEIN; CD4 ANTIBODY; CD71 ANTIGEN; COLLAGEN TYPE 1; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 210; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FOXP3; UNTRANSLATED RNA; MICRORNA; MIRN210 MICRORNA, HUMAN;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DOWN REGULATION; GENE CONTROL; GENE OVEREXPRESSION; HELICOBACTER INFECTION; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; LEISHMANIASIS; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PROTEIN EXPRESSION; REVIEW; RNA SEQUENCE; THERANOSTIC NANOMEDICINE; UPREGULATION; ANIMAL; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; GENETICS; IMMUNE SYSTEM DISEASES; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; HUMANS; IMMUNE SYSTEM DISEASES; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; THERANOSTIC NANOMEDICINE;

EID: 84991641341     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2016.1206890     Document Type: Review

References (140)

1. W.J.Peng, J.H.Tao, B.Mei, et al. MicroRNA-29:a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets. 2012;16(9):875–879.
2. X.Chen, H.Liang, J.Zhang, et al. Secreted microRNAs:a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125–132.
3. H.Valadi, K.Ekstrom, A.Bossios, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
4. K.C.Vickers, B.T.Palmisano, B.M.Shoucri, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–433.
5. R.I.Gregory, T.P.Chendrimada, N.Cooch, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631–640.
6. A.Lujambio, S.W.Lowe The microcosmos of cancer. Nature. 2012;482(7385):347–355.
7. L.Da Sacco, A.Masotti. Recent insights and Novel bioinformatics tools to understand the role of MicroRNAs binding to 5ʹ untranslated region. Int J Mol Sci. 2012;14(1):480–495.
8. S.Huang, S.Wu, J.Ding, et al. MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res. 2010;38(20):7211–7218.
9. S.Vasudevan, Y.Tong, J.A.Steitz. Switching from repression to activation:microRNAs can up-regulate translation. Science. 2007;318(5858):1931–1934.
10. L.P.Lim, N.C.Lau, P.Garrett-Engele, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773.
11. S.Y.Chan, J.Loscalzo. MicroRNA-210:a unique and pleiotropic hypoxamir. Cell Cycle. 2010;9(6):1072–1083.
12. X.Huang, L.Ding, B.Kl, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35(6):856–867.
13. T.Greither, L.F.Grochola, A.Udelnow, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126(1):73–80.
14. C.Camps, F.M.Buffa, S.Colella, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008;14(5):1340–1348.
15. X.Huang, Q.T.Le, A.J.Giaccia. MiR-210–micromanager of the hypoxia pathway. Trends Mol Med. 2010;16(5):230–237.
16. Y.Jiang, L.Li, X.Tan, et al. miR-210 mediates vagus nerve stimulation-induced antioxidant stress and anti-apoptosis reactions following cerebral ischemia/reperfusion injury in rats. J Neurochem. 2015;134(1):173–181.
17. Y.C.Chan, J.Banerjee, S.Y.Choi, et al. miR-210:the master hypoxamir. Microcirculation. 2012;19(3):215–223.
18. M.Z.Noman, S.Buart, P.Romero, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012;72(18):4629–4641.
19. Z.Chen, Y.Li, H.Zhang, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010;29(30):4362–4368.
20. R.Faraonio, P.Salerno, F.Passaro, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ. 2012;19(4):713–721.
21. T.Kushibiki. Photodynamic therapy induces microRNA-210 and −296 expression in HeLa cells. J Biophotonics. 2010;3(5–6):368–372.
22. P.Fasanaro, Y.D’Alessandra, V.Di Stefano, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–15883.
23. A.Hale, C.Lee, S.Annis, et al. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta. 2014;1843(11):2528–2542.
24. P.Fasanaro, S.Romani, C.Voellenkle, et al. ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One. 2012;7(9):e44651.
25. A.Magenta, S.Greco, C.Gaetano, et al. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci. 2013;14(9):17319–17346.
26. C.Nakada, Y.Tsukamoto, K.Matsuura, et al. Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol. 2011;224(2):280–288.
27. S.Biswas, S.Roy, J.Banerjee, et al. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA. 2010;107(15):6976–6981.•• The article is unique in presenting evidence demonstrating that the hypoxia component of ischemia may limit wound re-epithelialization by stabilizing HIF-1alpha, which induces miR-210 expression, resulting in the down-regulation of the cell-cycle regulatory protein E2F3.
28. H.Wang, S.Bian, C.S.Yang. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis. 2011;32(12):1881–1889.
29. S.Hu, M.Huang, Z.Li, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010;122(11 Suppl):S124–S131.
30. R.I.McCormick, C.Blick, J.Ragoussis, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108(5):1133–1142.
31. H.Yang, T.W.Li, J.Peng, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011;141(1):378–388, 388 e1–4.
32. M.P.Puissegur, N.M.Mazure, T.Bertero, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011;18(3):465–478.
33. R.Kulshreshtha, R.V.Davuluri, G.A.Calin, et al. A microRNA component of the hypoxic response. Cell Death Differ. 2008;15(4):667–671.
34. Y.Mok, V.Schwierzeck, D.C.Thomas, et al. MiR-210 is induced by Oct-2, regulates B cells, and inhibits autoantibody production. J Immunol. 2013;191(6):3037–3048.
35. R.K.Mutharasan, V.Nagpal, Y.Ichikawa, et al. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol. 2011;301(4):H1519–H1530.
36. S.Greco, C.Gaetano, F.Martelli. HypoxamiR regulation and function in ischemic cardiovascular diseases. Antioxid Redox Signal. 2014;21(8):1202–1219.
37. S.Muralimanoharan, C.Guo, L.Myatt, et al. Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity. Int J Obes (Lond). 2015;39(8):1274–1281.
38. S.C.Liu, S.M.Chuang, C.J.Hsu, et al. CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis. 2014;5:e1485.
39. S.Chapoval, P.Dasgupta, N.J.Dorsey, et al. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol. 2010;87(6):1011–1018.
40. H.Cui, B.Seubert, E.Stahl, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015;34(28):3640–3650.
41. J.H.Kim, S.G.Park, S.Y.Song, et al. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis. 2013;4:e588.
42. L.Xiong, F.Wang, X.Huang, et al. DNA demethylation regulates the expression of miR-210 in neural progenitor cells subjected to hypoxia. FEBS J. 2012;279(23):4318–4326.
43. A.Bye, H.Rosjo, S.T.Aspenes, et al. Circulating microRNAs and aerobic fitness–the HUNT-Study. PLoS One. 2013;8(2):e57496.
44. A.Merlo, S.B.de Quiros, I.S.de Santa-Maria, et al. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1alpha/miR-210 signaling pathway. J Clin Endocrinol Metab. 2013;98(10):E1661–E1666.
45. V.H.Tsang, T.Dwight, D.E.Benn, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014;21(3):415–426.
46. M.Selbach, B.Schwanhausser, N.Thierfelder, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63.
47. S.Tsuchiya, T.Fujiwara, F.Sato, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011;286(1):420–428.
48. A.Giannakakis, R.Sandaltzopoulos, J.Greshock, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008;7(2):255–264.
49. J.He, J.Wu, N.Xu, et al. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 2013;41(1):498–508.
50. X.Zhang, T.Zhu, Y.Chen, et al. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem. 2003;278(9):7580–7590.
51. G.L.Zhang, Y.X.Li, S.Q.Zheng, et al. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010;88(2):169–175.
52. K.Kiga, H.Mimuro, M.Suzuki, et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat Commun. 2014;5:4497.
53. A.L.Harris. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
54. Y.Yoshioka, N.Kosaka, T.Ochiya, et al. Micromanaging iron Homeostasis:hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem. 2012;287(41):34110–34119.
55. M.Okamoto, K.Nasu, W.Abe, et al. Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3. Hum Reprod. 2015;30(3):632–641.
56. L.Li, K.Huang, Y.You, et al. Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. Int J Oncol. 2014;44(6):2111–2120.
57. Q.D.Nguyen, A.Challapalli, G.Smith, et al. Imaging apoptosis with positron emission tomography:‘bench to bedside’ development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer. 2012;48(4):432–440.
58. R.C.Taylor, S.P.Cullen, S.J.Martin. Apoptosis:controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
59. A.M.Cheng, M.W.Byrom, J.Shelton, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–1297.
60. D.W.Lee, M.Futami, M.Carroll, et al. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012;31(37):4085–4094.
61. F.Wang, L.Xiong, X.Huang, et al. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res. 2013;11(1):657–667.
62. D.Gou, R.Ramchandran, X.Peng, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L682–L691.
63. W.Yang, T.Sun, J.Cao, et al. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012;318(8):944–954.
64. C.C.Chio, J.W.Lin, H.A.Cheng, et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol. 2013;87(3):459–468.
65. S.Y.Chan, Y.Y.Zhang, C.Hemann, et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10(4):273–284.
66. J.M.Link, S.Ota, Z.Q.Zhou, et al. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci USA. 2012;109(48):19685–19690.
67. M.Potente, H.Gerhardt, P.Carmeliet. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887.
68. P.Carmeliet, R.K.Jain. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
69. Y.Suarez, C.Fernandez-Hernando, J.Yu, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA. 2008;105(37):14082–14087.
70. J.A.Foekens, A.M.Sieuwerts, M.Smid, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 2008;105(35):13021–13026.
71. N.Kosaka, H.Iguchi, K.Hagiwara, et al. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013;288(15):10849–10859.
72. M.A.Alaiti, M.Ishikawa, H.Masuda, et al. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med. 2012;16(10):2413–2421.
73. F.Xiao, H.Qiu, L.Zhou, et al. WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology. 2013;23(5):524–535.
74. R.S.Bindra, M.E.Crosby, P.M.Glazer. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007;26(2):249–260.
75. M.E.Crosby, R.Kulshreshtha, M.Ivan, et al. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009;69(3):1221–1229.
76. S.A.Rosenberg, J.C.Yang, D.J.Schwartzentruber, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321–327.
77. H.Wang, H.Flach, M.Onizawa, et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol. 2014;15(4):393–401.•• The article suggests the role of the hypoxamir miR-210 in activation and differentiation of T cells, especially TH17.
78. D.A.Vignali, L.W.Collison, C.J.Workman. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532.
79. H.Fayyad-Kazan, R.Rouas, M.Fayyad-Kazan, et al. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem. 2012;287(13):9910–9922.
80. M.Zhao, L.T.Wang, G.P.Liang, et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol. 2014;150(1):22–30.
81. J.Qi, Y.Qiao, P.Wang, et al. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett. 2012;586(8):1201–1207.
82. L.M.Moore, W.Zhang. Targeting miR-21 in glioma:a small RNA with big potential. Expert Opin Ther Targets. 2010;14(11):1247–1257.
83. E.Bostjancic, N.Zidar, D.Glavac. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27(6):255–268.
84. T.Thum, P.Galuppo, C.Wolf, et al. MicroRNAs in the human heart:a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116(3):258–267.
85. T.Li, H.Cao, J.Zhuang, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 2011;412(1–2):66–70.
86. L.Zeng, J.Liu, Y.Wang, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed). 2011;3:1265–1272.
87. Y.L.Lou, F.Guo, F.Liu, et al. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem. 2012;370(1–2):45–51.
88. K.White, Y.Lu, S.Annis, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med. 2015;7(6):695–713.• This article demonstrates the miR-210-ISCU1/2 regulatory axis which is a pathogenic lynchpin causing Fe-S deficiency and PH.
89. L.K.Mathew, M.C.Simon. mir-210:a sensor for hypoxic stress during tumorigenesis. Mol Cell. 2009;35(6):737–738.
90. C.J.Cheng, R.Bahal, I.A.Babar, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107–110.
91. C.H.Lawrie, S.Gal, H.M.Dunlop, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–675.
92. Q.Ying, L.Liang, W.Guo, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011;54(6):2064–2075.
93. M.L.Taddei, L.Cavallini, G.Comito, et al. Senescent stroma promotes prostate cancer progression:the role of miR-210. Mol Oncol. 2014;8(8):1729–1746.
94. H.E.Gee, C.Camps, F.M.Buffa, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116(9):2148–2158.
95. M.Rivera-Diaz, M.A.Miranda-Roman, D.Soto, et al. MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res. 2015;5(1):201–218.
96. M.Eilertsen, S.Andersen, S.Al-Saad, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014;83(2):272–278.
97. E.J.Jung, L.Santarpia, J.Kim, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118(10):2603–2614.
98. P.Rotkrua, S.Shimada, K.Mogushi, et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108(4):932–940.
99. A.S.Ho, X.Huang, H.Cao, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010;3(2):109–113.
100. J.Wang, J.Chen, P.Chang, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807–813.
101. A.Qu, L.Du, Y.Yang, et al. Hypoxia-inducible miR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One. 2014;9(3):e90952.
102. A.Zhao, G.Li, M.Peoc’h, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115–120.
103. S.Eissa, M.Matboli, M.G.Hegazy, et al. Evaluation of urinary microRNA panel in bladder cancer diagnosis:relation to bilharziasis. Transl Res. 2015;165(6):731–739.
104. L.Quero, L.Dubois, N.G.Lieuwes, et al. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol. 2011;101(1):203–208.
105. B.Bao, A.Ahmad, D.Kong, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 2012;7(8):e43726.
106. Y.Mei, C.Gao, K.Wang, et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 2014;105(4):463–472.
107. P.S.Mitchell, R.K.Parkin, E.M.Kroh, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–10518.
108. J.H.Song, S.J.Meltzer. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143(1):35–47e2.
109. S.Mi, J.Lu, M.Sun, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104(50):19971–19976.
110. J.Shen, Z.Liu, N.W.Todd, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011;11:374.
111. H.Cai, L.Lin, H.Cai, et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 2013;30(2):499.
112. S.Qiu, S.Lin, D.Hu, et al. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.
113. T.Greither, P.Wurl, L.Grochola, et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012;130(5):1230–1235.
114. B.Yang, B.Liu, P.Bi, et al. An integrated analysis of differential miRNA and mRNA expressions in human gallstones. Mol Biosyst. 2015;11(4):1004–1011.
115. S.Hamama, M.Z.Noman, P.Gervaz, et al. MiR-210:a potential therapeutic target against radiation-induced enteropathy. Radiother Oncol. 2014;111(2):219–221.
116. J.M.Lorenzen, J.T.Kielstein, C.Hafer, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6(7):1540–1546.
117. J.Lemaire, G.Mkannez, F.Z.Guerfali, et al. MicroRNA expression profile in human macrophages in response to Leishmania major infection. PLoS Negl Trop Dis. 2013;7(10):e2478.
118. R.Perri, S.Nares, S.Zhang, et al. MicroRNA modulation in obesity and periodontitis. J Dent Res. 2012;91(1):33–38.
119. C.Stoecklin-Wasmer, P.Guarnieri, R.Celenti, et al. MicroRNAs and their target genes in gingival tissues. J Dent Res. 2012;91(10):934–940.
120. P.Xu, Y.Zhao, M.Liu, et al. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension. 2014;63(6):1276–1284.
121. Y.Zhang, M.Fei, G.Xue, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia:new insights into molecular mechanisms for the disease. J Cell Mol Med. 2012;16(2):249–259.
122. R.Luo, X.Shao, P.Xu, et al. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64(4):839–845.
123. N.Kosaka, K.Sugiura, Y.Yamamoto, et al. Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid differentiation. Br J Haematol. 2008;142(2):293–300.
124. N.Bianchi, C.Zuccato, I.Lampronti, et al. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 2009;42(8):493–499.
125. O.Sarakul, P.Vattanaviboon, Y.Tanaka, et al. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013;51(2):98–103.
126. G.H.Yang, F.Wang, J.Yu, et al. MicroRNAs are involved in erythroid differentiation control. J Cell Biochem. 2009;107(3):548–556.
127. J.Krutzfeldt, N.Rajewsky, R.Braich, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–689.
128. J.Elmen, M.Lindow, S.Schutz, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896–899.
129. I.A.Babar, C.J.Cheng, C.J.Booth, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA. 2012;109(26):E1695–E1704.
130. W.Yang, J.Wei, T.Guo, et al. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp Cell Res. 2014;326(1):22–35.
131. P.Fasanaro, S.Greco, M.Lorenzi, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284(50):35134–35143.
132. T.Shoji, T.Nakasa, K.Yamasaki, et al. The effect of intra-articular injection of microRNA-210 on ligament healing in a rat model. Am J Sports Med. 2012;40(11):2470–2478.
133. Y.Kawanishi, T.Nakasa, T.Shoji, et al. Intra-articular injection of synthetic microRNA-210 accelerates avascular meniscal healing in rat medial meniscal injured model. Arthritis Res Ther. 2014;16(6):488.
134. M.V.Iorio, C.M.Croce. MicroRNA dysregulation in cancer:diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–159.
135. D.Lee, S.Sun, X.Q.Zhang, et al. MicroRNA-210 and endoplasmic reticulum chaperones in the regulation of chemoresistance in glioblastoma. J Cancer. 2015;6(3):227–232.
136. J.Lu, F.Xie, L.Geng, et al. Potential role of MicroRNA-210 as biomarker in human cancers detection:a meta-analysis. Biomed Res Int. 2015;2015:303987.
137. L.Hong, Y.Han, H.Zhang, et al. miR-210:a therapeutic target in cancer. Expert Opin Ther Targets. 2013;17(1):21–28.• This review gives an overview of the role of miR-210 in cancer therapy.
138. M.P.Hamilton, K.Rajapakshe, S.M.Hartig, et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun. 2013;4:2730.
139. N.Rohwer, T.Cramer. Hypoxia-mediated drug resistance:novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191–201.
140. L.Hong, Y.Han, Y.Zhang, et al. MicroRNA-21:a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets. 2013;17(9):1073–1080.